Valo Therapeutics Limited, a cancer immunotherapy company developing neoantigen-coated oncolytic viruses as therapeutic vaccines has appointed Michael Stein to Chief Executive Officer. Stein already served as part-time co-Chairman since the companys inception in 2017.
Nobel Laureate Dr James Allison and Oncologist Dr Padmanee Sharma from the MD Anderson Cancer Center to join the company as Company Strategic Advisors
ReViral Ltd., a clinical-stage company focused on developing novel, antiviral compounds that target respiratory syncytial virus (RSV), today announced that Alex C. Sapir has been appointed Chief Executive Officer (CEO) and elected to the Board of Directors, effective June 10, 2019. Mr. Sapir succeeds Dr. Eddy Littler, who will serve as Chief Operating Officer (COO).
At its meeting on June 6th of 2019, Sanofi’s Board of Directors unanimously appointed Paul Hudson as Chief Executive Officer of the Group, to succeed Olivier Brandicourt who has decided to retire.
Sanofi has a new head of development, which the company confirmed on Wednesday with a short tweet: "Dietmar Berger, MD, PhD, joins #Sanofi as Head of Development, overseeing our clinical portfolio across all therapeutic areas and helping us bring transformative new medicines to patients."
Tomas Blomquist has been appointed as the new CEO and President of Biotage AB.
Dr. Martin Treder has informed Affimed that he intends to step down from his position as Chief Scientific Officer to pursue new opportunities.
Novel diagnostic developer PBD Biotech announces the appointment of new CEO Mark Hammond to drive the companys expansion.
Mogrify appoints 15 new staff including, Dr Karin Schmitt as Chief Business Officer and Joe Foster as Chief Operating Officer
Bionure, a biotech company specialized in neuroprotection, today announces that it has appointed Dr. Lucia Septien as chief medical officer.